Although there are clear reasons to target CCR-5, clinical studies on patients with active rheumatoid arthritis (RA) have shown that oral CCR-5 antagonist AZD5672 provides no clinical benefits, suggesting that the use of CCR-5 antagonists alone is unlikely to be a viable treatment strategy for RA (82). Here, CCR5 is linked to rheumatoid arthritis.